Status:
COMPLETED
The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment
Lead Sponsor:
Tuen Mun Hospital
Conditions:
Osteoporosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment
Detailed Description
We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases
Eligibility Criteria
Inclusion
- Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (\>=0.8mg/kg/day) or equivalent for at least 6 weeks.
- Age\>=18 years and \<75 years.
Exclusion
- Pregnant or lactating women.
- Uncorrected hypocalcemia.
- History of esophageal stricture.
- Previous intolerance or hypersenstivity to biphosphonates.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00372372
Start Date
January 1 2004
End Date
April 1 2007
Last Update
September 28 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tuen Mun Hospital
Hong Kong, China